Deep Vein Thrombosis Market
- As per American Lung Association (2023), pulmonary embolism can be life-threatening with 10-30% of individuals dying within one month of diagnosis. It affects around 900,000 people in the US every year.
- The Deep Vein Thrombosis epidemiology covered in the report provides historical as well as forecasted Persistent Epithelial Defect epidemiology [segmented as Total Incident Cases of Deep Vein Thrombosis, Age-specific Cases of Deep Vein Thrombosis, and Treatable Cases of Deep Vein Thrombosis in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.
Request for unlocking the CAGR of the “Deep Vein Thrombosis Market”
DelveInsight’s “Deep Vein Thrombosis Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the Deep Vein Thrombosis, historical and forecasted epidemiology as well as the Deep Vein Thrombosis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
The Deep Vein Thrombosis market report provides current treatment practices, emerging drugs, the market share of individual therapies, and current and forecasted Deep Vein Thrombosis market size from 2019 to 2032, segmented by the seven major markets. The report also covers the current Deep Vein Thrombosis treatment practices/algorithms and Deep Vein Thrombosis unmet needs to curate the best of the opportunities and assess the underlying potential of the market.
- The United States
- EU4 (Germany, France, Italy, and Spain) and the United Kingdom
Study period: 2019–2032
Deep Vein Thrombosis Treatment Algorithm and Market Understanding
DelveInsight’s Deep Vein Thrombosis market report gives a thorough understanding of Deep Vein Thrombosis by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.
Deep Vein Thrombosis Overview
Deep Vein Thrombosis is a blood clot that forms within the deep veins, usually of the leg, but can occur in the veins of the arms and the mesenteric and cerebral veins. It is part of the venous thromboembolism disorders which represent the third most common cause of death from cardiovascular disease after heart attacks and stroke. Deep Vein Thrombosis Symptoms can include pain, swelling, redness, and enlarged veins in the affected area, but some DVTs have no symptoms.
Blood clots may form if the blood flow in a vein is too slow, if there is a blood clotting disorder, or if the wall of a blood vessel is damaged. This can happen in the following cases:
- After longer periods of bed rest, for instance in hospital, after a bone fracture or injury. Staying in bed for a long time and not moving much can lead to poor blood circulation in your legs.
- Blood clotting disorders: Some people are born with a disease that makes their blood clot too much.
- More major operations: More major surgical procedures and serious injuries cause damage to blood vessels and activate the blood clotting (coagulation) system.
Various factors are responsible for increasing the risk of developing the risk for deep vein thrombosis. Some of them include older than 60 years, family history, heart failure, smoking, severely overweight, and certain inflammatory diseases.
It is a common venous thromboembolic (VTE) disorder with an incidence of 1.6 per 1000 annually. The rate of particular site involvement depends on the anatomical location as follows, distal veins 40%, popliteal 16%, femoral 20%, common femoral 20%, and iliac veins 4%.
Deep Vein Thrombosis Diagnosis
Deep vein thrombosis can’t be diagnosed for sure based on typical symptoms alone. Deep Vein Thrombosis symptoms such as pain, swelling, and red skin can be caused by other things too, including inflammation of superficial veins, varicose veins, erysipelas, or narrow leg arteries (peripheral artery disease, or PAD).
To diagnose deep vein thrombosis, a blood test called a D-dimer test is usually done first. This test reacts to substances that are released when blood clots are broken down. The substances are called D-dimers. If the results of the test are normal, doctors can be quite sure that you don’t have DVT. If the results are abnormal, a special kind of ultrasound scan (a Doppler ultrasound) is done to confirm the diagnosis. Doppler ultrasounds provide information about the condition of the deep veins and blood flow in the veins.
Deep Vein Thrombosis Treatment
In treating DVT, the main goal is to prevent a pulmonary embolus (PE). Other goals of treatment include preventing the clot from becoming larger, preventing new blood clots from forming, and preventing long-term complications. The treatment of DVT and PE are similar. In both cases, the primary approach is anticoagulation. Treatment with blood thinners may last from three to six months. If a blood clot develops after surgery, treatment may be shorter. If there have been previous clots or treatment for another illness is underway, the treatment may last as long as risk factors are present. The most common side effect of blood-thinning medication is bleeding. Bruising or bleeding should be reported to the physician right away.
The treatment is usually started with a medication that works quickly, such as heparin. Heparin should be initiated with an intravenous bolus of 5000 U followed either by an intravenous infusion of 1400 U/h or a subcutaneous injection of ≈17 500 U twice daily.
Other available treatments, which may be used in specific situations, include thrombolytic therapy or placing a filter in a major blood vessel (the inferior vena cava). In 2012, rivaroxaban became the first direct-acting oral anticoagulant approved by the US FDA for the treatment of DVT and PE. Several others followed. These agents belong to two classes: direct thrombin inhibitors (dabigatran) and direct factor Xa inhibitors (apixaban, edoxaban, and rivaroxaban).
Deep Vein Thrombosis Epidemiology
The Deep Vein Thrombosis epidemiology section provides insights into the historical and current Deep Vein Thrombosis patient pool and forecasted trends for seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Deep Vein Thrombosis report also provides the diagnosed patient pool, its trends, and the assumptions undertaken.
According to the Centers for Disease Control and Prevention (2023), the precise number of people affected by Deep Vein Thrombosis or pulmonary embolism (PE) is unknown, although as many as 900,000 people could be affected each year in the United States. Sudden death is the first symptom in about one-quarter (25%) of people who have PE. Estimates suggest that 60,000−100,000 Americans die of DVT/PE (also called venous thromboembolism, or VTE). Additionally, among people who have had a DVT, one-third to one-half will have long-term complications (post-thrombotic syndrome) such as swelling, pain, discoloration, and scaling in the affected limb. One-third (about 33%) of people with DVT/PE will have a recurrence within 10 years.
According to Anderson et al. (1991), a community-wide study was conducted in 16 short-stay hospitals in metropolitan Worcester, Mass, to examine the incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism in patients hospitalized between July 1, 1985, and December 31, 1986. The average annual incidence of deep vein thrombosis alone was 48 per 100,000, while the incidence of pulmonary embolism with or without deep vein thrombosis was 23 per 100,000. The incidence rates of deep vein thrombosis and pulmonary embolism increased exponentially with age. The in-hospital case-fatality rate of venous thromboembolism was 12%. Among patients discharged from the hospital, the long-term case-fatality rates were 19%, 25%, and 30% at 1, 2, and 3 years after hospital discharge. Extrapolation of the data from this population-based study suggests that there are approximately 170,000 new cases of clinically recognized venous thromboembolism in patients treated in short-stay hospitals in the United States each year and 99,000 hospitalizations for recurrent disease. Because of the silent nature of this disease and the low rate of autopsy in the United States, the total incidence, prevalence, and mortality rates of venous thromboembolism remain elusive.
As per American Lung Association (2023), pulmonary embolism can be life-threatening with 10-30% of individuals dying within one month of diagnosis. It affects around 900,000 people in the US every year.
The Deep Vein Thrombosis epidemiology covered in the report provides historical as well as forecasted Persistent Epithelial Defect epidemiology [segmented as Total Incident Cases of Deep Vein Thrombosis, Age-specific Cases of Deep Vein Thrombosis, and Treatable Cases of Deep Vein Thrombosis in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.
Country-wise Deep Vein Thrombosis Epidemiology
The epidemiology segment also provides the Deep Vein Thrombosis epidemiology data and findings across the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Deep Vein Thrombosis Drug Chapters
The drug chapter segment of the Deep Vein Thrombosis report encloses a detailed analysis of Deep Vein Thrombosis marketed drugs and late-stage (Phase III and Phase II) Deep Vein Thrombosis pipeline drugs. It also helps understand the Deep Vein Thrombosis clinical trials details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Emerging Deep Vein Thrombosis Drugs
The report details the emerging Deep Vein Thrombosis therapies under the late and mid-stage of development for Deep Vein Thrombosis treatment.
Deep Vein Thrombosis Market Outlook
The Deep Vein Thrombosis market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Deep Vein Thrombosis market trends by analyzing the impact of current therapies on the market, Deep Vein Thrombosis unmet needs, and demand for better technology.
This segment gives a thorough detail of the Deep Vein Thrombosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Deep Vein Thrombosis market in the 7MM is expected to witness a major change in the study period 2019–2032.
This section includes a glimpse of the Deep Vein Thrombosis market in the 7MM.
The United States: Deep Vein Thrombosis Market Outlook
This section provides the total Deep Vein Thrombosis market size and market size by therapies in the United States.
EU4 and the United Kingdom: Deep Vein Thrombosis Market Outlook
The total Deep Vein Thrombosis market size and market size by therapies in EU4 (Germany, France, Italy, and Spain) and the United Kingdom are provided in this section.
Japan: Deep Vein Thrombosis Market Outlook
The total Deep Vein Thrombosis market size and market size by therapies in Japan are also mentioned.
2019 to 2032
2023 to 2032
Deep Vein Thrombosis Market Size
USD XX Million by 2032
Key Deep Vein Thrombosis Companies
Bristol Myers Squibb (BMS), Pfizer Inc., Johnson & Johnson, Sanofi, Bayer AG, Novartis International AG, Eli Lilly and Company, Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Portola Pharmaceuticals, Inc. (acquired by Alexion Pharmaceuticals, Inc.), and Many Others.
Deep Vein Thrombosis Drug Uptake
This section focuses on the rate of uptake of the potential drugs recently launched in the Deep Vein Thrombosis market or expected to get launched in the market during the study period 2019–2032. The analysis covers Deep Vein Thrombosis market uptake by drugs, patient uptake by therapies, and sales of each drug.
This will help in understanding the Deep Vein Thrombosis drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.
Deep Vein Thrombosis Pipeline Development Activities
The report provides insights into Deep Vein Thrombosis Clinical Trials within Phase II and Phase III stages. It also analyses the Deep Vein Thrombosis companies involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers detailed information on collaborations, acquisitions, and mergers, licensing patent details, and other information for Deep Vein Thrombosis emerging therapies.
Deep Vein Thrombosis Reimbursement Scenario
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
To keep up with current epidemiology and market trends, we take KOLs and SMEs' opinions working in the Deep Vein Thrombosis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies and treatment patterns along with Deep Vein Thrombosis market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the Deep Vein Thrombosis unmet needs.
Competitive Intelligence Analysis
We perform competitive and market intelligence analysis of the Deep Vein Thrombosis market by using various competitive intelligence tools that include – SWOT analysis and Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Deep Vein Thrombosis Market Report
- Descriptive overview of Deep Vein Thrombosis, disease overview, patient journeys, treatment algorithms, diagnosis, and currently available therapies.
- Comprehensive insight into the Deep Vein Thrombosis epidemiology and forecasts in the 7MM.
- An all-inclusive account of both the current and emerging therapies for Deep Vein Thrombosis, along with the assessment of new therapies, is expected to have an impact on the current treatment landscape.
- Exhaustive analysis of the Deep Vein Thrombosis market; historical and forecasted covering drug outreach in the 7MM.
- Detailed patient-based Deep Vein Thrombosis market forecasting determines the trends shaping and driving the global Deep Vein Thrombosis market.
Deep Vein Thrombosis Market Report Highlights
- In the coming years, the Deep Vein Thrombosis market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The Deep Vein Thrombosis companies and academics are working to assess challenges and seek opportunities that could influence Deep Vein Thrombosis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- Deep Vein Thrombosis companies are involved in developing Deep Vein Thrombosis therapies. The launch of emerging therapies will significantly impact the Deep Vein Thrombosis market.
- A better understanding of Deep Vein Thrombosis pathogenesis will also contribute to the development of novel therapeutics for Deep Vein Thrombosis.
- Our in-depth analysis of the Deep Vein Thrombosis pipeline assets across different stages of development (Phase III and Phase II), emerging trends, and comparative analysis of pipeline products with detailed Deep Vein Thrombosis clinical trials profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Deep Vein Thrombosis Report Insights
- Patient-Based Deep Vein Thrombosis Market Forecasting
- Deep Vein Thrombosis Therapeutic approaches
- Deep Vein Thrombosis pipeline analysis
- Deep Vein Thrombosis market size and trends
- Deep Vein Thrombosis market opportunities
- Impact of Upcoming Deep Vein Thrombosis Therapies
Deep Vein Thrombosis Report Key Strengths
- 10 years forecast
- The 7MM Coverage
- Deep Vein Thrombosis epidemiology segmentation
- Key cross competition
- KOL views
- Deep Vein Thrombosis drugs uptake
Deep Vein Thrombosis Report Assessment
- Current Deep Vein Thrombosis treatment practices
- Deep Vein Thrombosis Unmet needs
- Deep Vein Thrombosis pipeline product profiles
- Deep Vein Thrombosis market attractiveness
- Deep Vein Thrombosis Market Drivers
- Deep Vein Thrombosis Market Barriers
Key Questions Answered In The Deep Vein Thrombosis Market Report
Deep Vein Thrombosis market insights:
- What would be the Deep Vein Thrombosis market growth till 2032, and what will be the resultant market size in 2032?
- What was the Deep Vein Thrombosis drug class share (in percentage) distribution in 2019, and how would it look in 2032?
- What would be the Deep Vein Thrombosis total market size and market size by therapies across the 7MM during the forecast period (2023–2032)?
- What are the key findings of the market across the 7MM, and which country will have the largest Deep Vein Thrombosis market size during the forecast period (2023–2032)?
- How would the unmet needs affect the Deep Vein Thrombosis market dynamics and subsequent analysis of the associated trends?
Deep Vein Thrombosis Epidemiology Insights:
- What are the disease risk, burden, and regional/ethnic differences of Deep Vein Thrombosis?
- What is the historical and forecasted Deep Vein Thrombosis patient pool in the 7MM, and where can one observe the highest patient population and growth opportunities?
- What are the key factors driving the epidemiology trends for seven major markets covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
Current Deep Vein Thrombosis Treatment Scenario, Marketed Drugs, and Emerging Therapies
- What are the current treatment guidelines and treatment options, in addition to approved therapies for Deep Vein Thrombosis in the US, Europe, and Japan?
- What are the key collaborations (Industry–Industry, Industry-Academia), mergers and acquisitions, and licensing activities related to Deep Vein Thrombosis therapies?
- What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Deep Vein Thrombosis and its status, along with the challenges faced?
Reasons to Buy Deep Vein Thrombosis Market Report
- The patient-based Deep Vein Thrombosis market forecasting analysis will help in developing business strategies by understanding trends shaping and driving the Deep Vein Thrombosis market.
- Organize sales and marketing efforts by identifying the best opportunities for Deep Vein Thrombosis in the US, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.
- Identification of strong upcoming players in the market that will help devise strategies that will help in getting ahead of competitors.